Effects of recombinant human erythropoietin treatment in end-stage renal failure patients. Results of a multicenter phase II/III study.
Pollok
M
M
Department of Nephrology, University Hospital, Cologne, FRG.
Bommer
J
J
Gurland
H J
HJ
Koch
K M
KM
Schoeppe
W
W
Scigalla
P
P
Baldamus
C A
CA
D000328:Adult; D000368:Aged; D000740:Anemia / Q000097:blood / Q000188:drug therapy / Q000209:etiology; D004906:Erythrocyte Count; D004921:Erythropoietin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006400:Hematocrit; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D011897:Random Allocation; D006435:Renal Dialysis; D012156:Reticulocytes; D013927:Thrombosis / Q000139:chemically induced
D004921:Erythropoietin